Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2016 (2016), Article ID 5896061, 11 pages
http://dx.doi.org/10.1155/2016/5896061
Review Article

Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells

1Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China
2Department of Radiology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China
3Department of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang, Hebei 050017, China
4School of Nursing, Hebei Medical University, Shijiazhuang, Hebei 050000, China
5Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, China

Received 14 February 2016; Accepted 12 April 2016

Academic Editor: Joost Sluijter

Copyright © 2016 Shujing Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Ischemic diseases are a group of diseases, including ischemic cerebrovascular disease, ischemic cardiomyopathy (ICM), and diabetic foot as well as other diseases which are becoming a leading cause of morbidity and mortality in the whole world. Mesenchymal stem cells (MSCs) have been used to treat a variety of ischemic diseases in animal models and clinical trials. Lots of recent publications demonstrated that MSCs therapy was safe and relieved symptoms in patients of ischemic disease. However, many factors could influence therapeutic efficacy including route of delivery, MSCs’ survival and residential rate in vivo, timing of transplantation, particular microenvironment, and patient’s clinical condition. In this review, the current status, therapeutic potential, and the detailed factors of MSCs-based therapeutics for ischemic cerebrovascular disease, ICM, and diabetic foot are presented and discussed. We think that MSCs transplantation would constitute an ideal option for patients with ischemic diseases.